(0.10%) 5 522.25 points
(0.14%) 39 898 points
(0.19%) 19 789 points
(-0.06%) $81.58
(0.57%) $2.83
(-0.23%) $2 339.00
(0.17%) $29.58
(0.45%) $1 006.30
(0.05%) $0.932
(-0.02%) $10.53
(0.02%) $0.788
(-0.85%) $87.25
1.12% $ 0.650
Live Chart Being Loaded With Signals
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States...
Stats | |
---|---|
Dzisiejszy wolumen | 463 315 |
Średni wolumen | 625 850 |
Kapitalizacja rynkowa | 47.32M |
EPS | $-0.300 ( Q1 | 2024-05-09 ) |
Następna data zysków | ( $-0.320 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.470 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00100 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-20 | Wallace Courtney | Buy | 50 000 | Stock Option (right to buy) |
2024-06-20 | Garner Elizabeth | Buy | 50 000 | Stock Option (right to buy) |
2024-06-20 | Cooper Graham K | Buy | 50 000 | Stock Option (right to buy) |
2024-06-20 | Klearman Micki | Buy | 50 000 | Stock Option (right to buy) |
2024-06-20 | Kauffman Michael | Buy | 50 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
-10.04 |
Last 100 transactions |
Buy: 7 765 931 | Sell: 10 044 723 |
Wolumen Korelacja
Kezar Life Sciences Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje | |
---|---|
RILYM | -0.809 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Kezar Life Sciences Inc Korelacja - Waluta/Towar
Kezar Life Sciences Inc Finanse
Annual | 2023 |
Przychody: | $7.00M |
Zysk brutto: | $5.93M (84.77 %) |
EPS: | $-1.400 |
FY | 2023 |
Przychody: | $7.00M |
Zysk brutto: | $5.93M (84.77 %) |
EPS: | $-1.400 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-1.02M (0.00 %) |
EPS: | $-0.970 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.00102 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej